<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Irina Kislaya</style></author><author><style face="normal" font="default" size="100%">Alexis Sentís</style></author><author><style face="normal" font="default" size="100%">Jostein Starrfelt</style></author><author><style face="normal" font="default" size="100%">Baltazar Nunes</style></author><author><style face="normal" font="default" size="100%">Iván Martínez-Baz</style></author><author><style face="normal" font="default" size="100%">Katrine Finderup Nielsen</style></author><author><style face="normal" font="default" size="100%">Ala'a AlKerwi</style></author><author><style face="normal" font="default" size="100%">Toon Braeye</style></author><author><style face="normal" font="default" size="100%">Mario Fontán-Vela</style></author><author><style face="normal" font="default" size="100%">Sabrina Bacci</style></author><author><style face="normal" font="default" size="100%">Hinta Meijerink</style></author><author><style face="normal" font="default" size="100%">Jesús Castilla</style></author><author><style face="normal" font="default" size="100%">Hanne-Dorthe Emborg</style></author><author><style face="normal" font="default" size="100%">Christian Holm Hansen</style></author><author><style face="normal" font="default" size="100%">Susanne Schmitz</style></author><author><style face="normal" font="default" size="100%">Izaak Van Evercooren</style></author><author><style face="normal" font="default" size="100%">Marta Valenciano</style></author><author><style face="normal" font="default" size="100%">Anthony Nardone</style></author><author><style face="normal" font="default" size="100%">Nathalie Nicolay</style></author><author><style face="normal" font="default" size="100%">Susana Monge</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">VEBIS-Lot4 working group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.</style></title><secondary-title><style face="normal" font="default" size="100%">Influenza Other Respir Viruses</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">Electronics</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">REGISTRIES</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Within the ECDC-VEBIS project, we prospectively monitored vaccine effectiveness (VE) against COVID-19 hospitalisation and COVID-19-related death using electronic health registries (EHR), between October 2021 and November 2022, in community-dwelling residents aged 65-79 and ≥80 years in six European countries.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;EHR linkage was used to construct population cohorts in Belgium, Denmark, Luxembourg, Navarre (Spain), Norway and Portugal. Using a common protocol, for each outcome, VE was estimated monthly over 8-week follow-up periods, allowing 1 month-lag for data consolidation. Cox proportional-hazards models were used to estimate adjusted hazard ratios (aHR) and VE = (1&amp;nbsp;- aHR) × 100%. Site-specific estimates were pooled using random-effects meta-analysis.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;For ≥80 years, considering unvaccinated as the reference, VE against COVID-19 hospitalisation decreased from 66.9% (95% CI: 60.1; 72.6) to 36.1% (95% CI: -27.3; 67.9) for the primary vaccination and from 95.6% (95% CI: 88.0; 98.4) to 67.7% (95% CI: 45.9; 80.8) for the first booster. Similar trends were observed for 65-79 years. The second booster VE against hospitalisation ranged between 82.0% (95% CI: 75.9; 87.0) and 83.9% (95% CI: 77.7; 88.4) for the ≥80 years and between 39.3% (95% CI: -3.9; 64.5) and 80.6% (95% CI: 67.2; 88.5) for 65-79 years. The first booster VE against COVID-19-related death declined over time for both age groups, while the second booster VE against death remained above 80% for the ≥80 years.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Successive vaccine boosters played a relevant role in maintaining protection against COVID-19 hospitalisation and death, in the context of decreasing VE over time. Multicountry data from EHR facilitate robust near-real-time VE monitoring in the EU/EEA and support public health decision-making.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue></record></records></xml>